CEO Mark Lappe's $2.6 million share purchase underscores internal optimism at Inhibrx Biosciences as the clinical-stage firm advances its proprietary protein engineering platform.
CEO Mark Lappe's $2.6M open-market purchase and positive INBRX-106 trial results signal strong insider confidence in Inhibrx's clinical pipeline.
Inhibrx Biosciences CEO Mark Lappe acquired 25,000 shares in an open-market transaction valued at $2.6 million. This insider purchase follows positive clinical trial results for the company's INBRX-106 therapeutic candidate, signaling strong leadership confidence in the firm's pipeline.
In financial markets, insider buying is often interpreted as a bullish signal, as it suggests the executive believes the company's share price is undervalued or poised for growth.